Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
August 03 2020 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that it will host a live
conference call and audio webcast on Monday, August 10, 2020 at
8:30 a.m. ET to report financial results for the second quarter
ended June 30, 2020, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056
(domestic) or (678) 809-1043 (international) at least five minutes
prior to the start time, and refer to conference ID 3334648. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound
derived from porcine heparin that, compared to commercially
available forms of heparin, may be dosed at higher levels without
associated bleeding complications. DSTAT is being studies in
a Phase 2/3 trial to assess safety and efficacy in adults with
acute lung injury with underlying severe COVID-19 infection.
A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia
(AML) has been agreed to with the US Food and Drug Administration
(FDA).
BCV is an antiviral drug candidate in development as a medical
countermeasure for smallpox. For further information, please visit
the Chimerix website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things, the
mechanism of action of DSTAT and its potential; Chimerix’s ability
to develop DSTAT, including the initiation of a Phase 3 trial in
AML and the ongoing Phase 2/3 clinical trial for DSTAT as a
potential treatment for ALI associated with COVID-19; Chimerix’s
ability to submit and/or obtain regulatory approvals for DSTAT and
BCV; and the timing and receipt of a potential procurement contract
for BCV in smallpox. Among the factors and risks that could cause
actual results to differ materially from those indicated in the
forward-looking statements are risks that DSTAT may not achieve the
endpoints of its clinical trials; risks that DSTAT may not obtain
regulatory approval from the FDA or such approval may be delayed or
conditioned; risks that development activities related to DSTAT may
not be completed on time or at all; Chimerix’s reliance on a sole
source third-party manufacturer for drug supply; risks that ongoing
or future trials may not be successful or replicate previous trial
results, or may not be predictive of real-world results or of
results in subsequent trials; risks and uncertainties relating to
competitive products and technological changes that may limit
demand for our drugs; risks that our drugs may be precluded from
commercialization by the proprietary rights of third parties; and
additional risks set forth in the Company's filings with the
Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
CONTACT:
Investor
Relations:
Michelle LaSpaluto 919 972-7115 ir@chimerix.com Will O’Connor Stern
Investor Relations 212-362-1200will@sternir.com Media: David Schull
Russo Partners 858-717-2310 David.Schull@russopartnersllc.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024